Name: PROTAC IRAK4 degrader-1
Brand: BOC Sciences
Rating: 5 (1 reviews)

Size

Price

Stock

Quantity

$--

In stock

Purity

≥95%

Solubility

Soluble in DMSO

Appearance

Solid

Storage

Store at -20°C

IUPACName

2-[2-(cyclopropylmethylamino)pyridin-4-yl]-N-[1-[4-[3-[4-[[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]methyl]imidazol-1-yl]propylcarbamoyl]phenyl]-3-(trifluoromethyl)pyrazol-4-yl]-1,3-oxazole-4-carboxamide

Synonyms

2-{2-[(Cyclopropylmethyl)amino]-4-pyridinyl}-N-{1-[4-({3-[4-({[2-(2,6-dioxo-3-piperidinyl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}methyl)-1H-imidazol-1-yl]propyl}carbamoyl)phenyl]-3-(trifluoromethyl)-1H-pyrazol-4-yl}-1,3-oxazole-4-carboxamide; 4-Oxazolecarboxamide, 2-[2-[(cyclopropylmethyl)amino]-4-pyridinyl]-N-[1-[4-[[[3-[4-[[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]methyl]-1H-imidazol-1-yl]propyl]amino]carbonyl]phenyl]-3-(trifluoromethyl)-1H-pyrazol-4-yl]-

Density

1.6±0.1 g/cm3

InChI Key

YXSXFMHKDNIZFS-UHFFFAOYSA-N

InChI

InChI=1S/C44H39F3N12O7/c45-44(46,47)37-31(53-39(62)32-22-66-41(54-32)26-13-15-48-34(17-26)51-18-24-5-6-24)21-58(56-37)28-9-7-25(8-10-28)38(61)49-14-2-16-57-20-27(52-23-57)19-50-30-4-1-3-29-36(30)43(65)59(42(29)64)33-11-12-35(60)55-40(33)63/h1,3-4,7-10,13,15,17,20-24,33,50H,2,5-6,11-12,14,16,18-19H2,(H,48,51)(H,49,61)(H,53,62)(H,55,60,63)

SMILES

C1CC1CNC2=NC=CC(=C2)C3=NC(=CO3)C(=O)NC4=CN(N=C4C(F)(F)F)C5=CC=C(C=C5)C(=O)NCCCN6C=C(N=C6)CNC7=CC=CC8=C7C(=O)N(C8=O)C9CCC(=O)NC9=O

Mechanism

Target: Targets IRAK4 kinase scaffolding protein for experimental targeted protein degradation studies.

Binding Site: Binds the IRAK4 kinase domain and cereblon thalidomide-binding pocket to support productive ternary complex formation.

Mechanism of Action: PROTAC IRAK4 degrader-1 is designed for use in PROTAC or targeted protein degradation experiments directed toward IRAK4 kinase scaffolding protein. The bifunctional molecule links a target-recognition element to cereblon, promoting proximity between the protein of interest and ubiquitination machinery. Productive ternary-complex formation can drive polyubiquitination and proteasome-dependent target depletion, allowing researchers to compare pharmacological inhibition with protein removal. It is suitable for evaluating degradation potency, kinetics, pathway selectivity, and downstream signaling consequences in engineered or disease-relevant cellular models.

Applications

• PROTAC-Mediated IRAK4 Degradation: This PROTAC IRAK4 degrader-1 is designed for the targeted degradation of interleukin-1 receptor-associated kinase 4 (IRAK4). It is instrumental in studying the modulation of IRAK4-dependent signaling pathways, offering insights into inflammatory responses and immune system regulation.

• Inflammation Pathway Investigation: Utilize PROTAC IRAK4 degrader-1 to dissect the role of IRAK4 in inflammation-related pathways. By selectively degrading IRAK4, researchers can elucidate its function and interaction with other proteins, facilitating the exploration of novel anti-inflammatory therapeutic strategies.

• Signal Transduction Analysis: Employ PROTAC IRAK4 degrader-1 to examine the impact of IRAK4 degradation on signal transduction processes. This application aids in understanding the downstream effects of IRAK4 removal, providing a deeper comprehension of cellular communication mechanisms in immune responses.

• Immune System Research: Leverage the targeted degradation capabilities of PROTAC IRAK4 degrader-1 to study immune system dynamics. By depleting IRAK4, researchers can investigate its role in innate immunity and its potential as a target for modulating immune functions in various diseases.

Stock concentration: *

Desired final volume: *

Desired concentration: *

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C₁V₁ = C₂V₂